» Articles » PMID: 7049208

Pindolol--the Pharmacology of a Partial Agonist

Overview
Specialty Pharmacology
Date 1982 Jan 1
PMID 7049208
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

1 Pindolol is a non-selective beta-adrenoceptor blocking agent; its affinity to adrenoceptors in guinea pig atria (beta 1) is not significantly different from that in guinea pig trachea (beta 1 + beta 2) and canine vascular smooth muscle (beta 2). 2 Pindolol displays a striking diversity of agonist activities in isolated tissues. Stimulant effects correspond to 40--50% of the maximum effects of isoprenaline in isolated kitten atria and guinea pig trachea and to only 10% in guinea pig atria. Effects in canine isolated mesenteric vessels are those of a full agonist, maximum responses equaling those of isoprenaline. These findings suggest that the stimulant effects of pindolol are exerted principally on beta 2-adrenoceptors. 3 Cardiac stimulation produced by pindolol in the dog is sufficient to compensate for the cardiac depression resulting from blockade of beta-adrenoceptors in the heart. Reductions in cardiac output and compensatory increases in total peripheral resistance do not occur or are much smaller than those produced by beta-adrenoceptor blocking agents lacking sympathomimetic activity. 4 Pindolol-induced relaxation of bronchial smooth muscle prevents or minimizes the bronchoconstrictor effects of injected spasmogens in the cat. 5 Pindolol has marked vasodilator activity, small doses reducing femoral and mesenteric vascular resistance by approximately 30%. Doses comparable to those used in hypertensive patients lower blood pressure by 20 mmHg in non-anaesthetized dogs.

Citing Articles

Pharmacokinetics, Pharmacodynamics and Bioavailability of ACM-001.1 (S-Pindolol Benzoate) in Healthy Volunteers.

Misselwitz F, Henderson D, Menakuru S, Morten E, Roe C, Whitaker G J Cachexia Sarcopenia Muscle. 2024; 16(1):e13651.

PMID: 39665235 PMC: 11670174. DOI: 10.1002/jcsm.13651.


Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies.

Zeng W, Han C, Mohammed S, Li S, Song Y, Sun F RSC Med Chem. 2024; 15(3):788-808.

PMID: 38516587 PMC: 10953485. DOI: 10.1039/d3md00677h.


Peripheral vasoconstriction induced by β-adrenoceptor blockers: a systematic review and a network meta-analysis.

Khouri C, Jouve T, Blaise S, Carpentier P, Cracowski J, Roustit M Br J Clin Pharmacol. 2016; 82(2):549-60.

PMID: 27085011 PMC: 4972171. DOI: 10.1111/bcp.12980.


Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors.

Joseph S, Lynham J, Molenaar P, Grace A, Colledge W, Kaumann A Naunyn Schmiedebergs Arch Pharmacol. 2003; 368(6):496-503.

PMID: 14608456 DOI: 10.1007/s00210-003-0835-z.


Conversion of agonist site to metal-ion chelator site in the beta(2)-adrenergic receptor.

Elling C, Thirstrup K, Holst B, Schwartz T Proc Natl Acad Sci U S A. 1999; 96(22):12322-7.

PMID: 10535920 PMC: 22915. DOI: 10.1073/pnas.96.22.12322.


References
1.
Barrett A, Carter J . Comparative chronotropic activity of beta-adrenoceptive antagonists. Br J Pharmacol. 1970; 40(3):373-81. PMC: 1703170. DOI: 10.1111/j.1476-5381.1970.tb10619.x. View

2.
Lang E, Holtmann W . [Changes in hemodynamics under the effect of two beta sympathicolytics of various pharmacodynamic principle]. Arzneimittelforschung. 1974; 24(9):1330-5. View

3.
Tsukiyama H, Otsuka K, Miyamoto K, Hashimoto M, Yasutake S . Hemodynamic effects of beta-adrenergic blockade with pindolol, oxprenolol, propranolol and bufetolol hydrochloride in essential hypertension. Jpn Circ J. 1976; 40(6):655-64. DOI: 10.1253/jcj.40.655. View

4.
Atterhog J, DUNER H, PERNOW B . Experience with pindolol, a betareceptor blocker, in the treatment of hypertension. Am J Med. 1976; 60(6):872-6. DOI: 10.1016/0002-9343(76)90907-4. View

5.
SIMPSON W . Nature and incidence of unwanted effects with atenolol. Postgrad Med J. 1977; 53 Suppl 3:162-7. View